{'52WeekChange': -0.2571898,
 'SandP52WeekChange': 0.0644362,
 'address1': '16 Tiomkin Street',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 4.7,
 'askSize': 900,
 'averageDailyVolume10Day': 222625,
 'averageVolume': 91215,
 'averageVolume10days': 222625,
 'beta': 2.521008,
 'beta3Year': None,
 'bid': 4.46,
 'bidSize': 900,
 'bookValue': 3.03,
 'category': None,
 'circulatingSupply': None,
 'city': 'Tel Aviv',
 'companyOfficers': [],
 'country': 'Israel',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 4.57,
 'dayLow': 4.46,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -1.091,
 'enterpriseToRevenue': None,
 'enterpriseValue': 27025310,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '972 3 693 8447',
 'fiftyDayAverage': 4.9525714,
 'fiftyTwoWeekHigh': 7.38,
 'fiftyTwoWeekLow': 3.02,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 14385422,
 'forwardEps': -1.52,
 'forwardPE': -2.9736843,
 'fromCurrency': None,
 'fullTimeEmployees': 17,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.21357,
 'heldPercentInstitutions': 0.33699,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/galmedpharma.com',
 'longBusinessSummary': 'Galmed Pharmaceuticals Ltd., a clinical-stage '
                        'biopharmaceutical company, focuses on the development '
                        'of therapeutics for the treatment of liver diseases. '
                        'The company is develops Aramchol, an oral therapy, '
                        'which is completed ARREST Phase IIb clinical study '
                        'for the treatment of patients with overweight or '
                        'obesity, and who are pre-diabetic or type-II-diabetic '
                        'with non-alcoholic steato-hepatitis. It also '
                        'evaluates Aramchol through ARRIVE Study, a '
                        'proof-of-concept Phase IIa clinical trial, with '
                        'HIV-associated non-alcoholic fatty liver disease and '
                        'lipodystrophy. The company was founded in 2000 and is '
                        'headquartered in Tel Aviv, Israel.',
 'longName': 'Galmed Pharmaceuticals Ltd.',
 'market': 'us_market',
 'marketCap': 95431208,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_114779940',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -23032000,
 'nextFiscalYearEnd': 1640908800,
 'open': 4.53,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.17,
 'phone': '972 3 693 8448',
 'previousClose': 4.55,
 'priceHint': 4,
 'priceToBook': 1.4917492,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 4.57,
 'regularMarketDayLow': 4.46,
 'regularMarketOpen': 4.53,
 'regularMarketPreviousClose': 4.55,
 'regularMarketPrice': 4.53,
 'regularMarketVolume': 108719,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 21113100,
 'sharesPercentSharesOut': 0.022,
 'sharesShort': 465462,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 371992,
 'shortName': 'Galmed Pharmaceuticals Ltd.',
 'shortPercentOfFloat': 0.026400002,
 'shortRatio': 6.58,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'GLMD',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.091,
 'twoHundredDayAverage': 4.9392805,
 'volume': 108719,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.galmedpharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '6578317'}